Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease
Sonika Sethi, Shiluka Dias, Aditi Kumar, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 12, pp. 1362-1374
Open Access | Times Cited: 43

Showing 26-50 of 43 citing articles:

Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease
Liang Chen, Dengfeng Kang, Leilei Fang, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study
Rodrigo Bremer Nones, Eron Fábio Miranda, Gustavo de Nardi Marçal, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 7, pp. 711-720
Closed Access
Lateral flow test versus enzyme‐linked immunosorbent assay to measure infliximab trough concentrations: A head‐to‐head comparison
Marleen Bouhuys, Margreet Wessels, Willemien de Vries, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024)
Open Access
Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
Susana Clemente, Óscar Segarra Cantón, Núria Padullés Zamora, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1577-1577
Open Access
Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics
Srđan Marković, Đorđe Kralj, Petar Svorcan, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1629-1629
Open Access
A prediction method for the individual serum concentration and therapeutic effect for optimizing adalimumab therapy in inflammatory bowel disease
Koji Kimura, Atsushi Yoshida
Journal of Pharmacy and Pharmacology (2024)
Closed Access
Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents
Omar I. Saadah, Turki AlAmeel, Ahmed Al Sarkhy, et al.
Saudi Journal of Gastroenterology (2024)
Open Access
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis
Yang Hu, Zaiwei Song, Yuan Gao, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 10, pp. 935-948
Open Access
Therapeutic drug monitoring for immune mediated inflammatory diseases
Neil Chanchlani, Z.Z.N. Yiu, Lisa K. Stamp, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e001130-e001130
Open Access
Review and External Evaluation of Population Pharmacokinetic Models for Vedolizumab in Patients with Inflammatory Bowel Disease: Assessing Predictive Performance and Clinical Applicability
Marija Jovanović, Ana Homšek, Srdjan Marković, et al.
Biomedicines (2024) Vol. 13, Iss. 1, pp. 43-43
Open Access
Editorial: proactive anti‐TNF drug monitoring in IBD—Ready for prime time?
Xavier Roblin, Stéphane Nancey
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 12, pp. 1453-1454
Open Access | Times Cited: 1
Point-of-Care Assays for Infliximab Therapeutic Drug Monitoring in Patients with IBD: Is Quicker Better?
Steven Levitte
Digestive Diseases and Sciences (2023)
Open Access | Times Cited: 1
Editorial: proactive anti‐TNF drug monitoring in IBD—Ready for the prime time? Authors' reply
Sonika Sethi, Aditi Kumar, Shiluka Dias, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 12, pp. 1455-1456
Open Access
Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis
Michal Prokopič, Georgiana Gilca-Blanariux, Peter Lietava, et al.
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access
Using a Treat-to-Target Approach to Manage Patients With Inflammatory Bowel Disease.
Cynthia H. Seow
PubMed (2023) Vol. 19, Iss. 7, pp. 415-417
Closed Access
A Message from the Editors
Colin W. Howden, Rohit Loomba
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 1, pp. 4-5
Open Access
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study
Rodrigo Bremer Nones, Eron Fábio Miranda, Gustavo de Nardi Marçal, et al.
Gastroenterología y Hepatología (2023) Vol. 47, Iss. 7, pp. 711-720
Closed Access
Previous Page - Page 2

Scroll to top